227 related articles for article (PubMed ID: 38254738)
1. Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer.
Verma S; Swain D; Kushwaha PP; Brahmbhatt S; Gupta K; Sundi D; Gupta S
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254738
[TBL] [Abstract][Full Text] [Related]
2. The MAGE protein family and cancer.
Weon JL; Potts PR
Curr Opin Cell Biol; 2015 Dec; 37():1-8. PubMed ID: 26342994
[TBL] [Abstract][Full Text] [Related]
3. Cancer-testis antigens MAGEA proteins are incorporated into extracellular vesicles released by cells.
Kuldkepp A; Karakai M; Toomsoo E; Reinsalu O; Kurg R
Oncotarget; 2019 Jun; 10(38):3694-3708. PubMed ID: 31217903
[TBL] [Abstract][Full Text] [Related]
4. Pathogenicity of the MAGE family.
Li S; Shi X; Li J; Zhou X
Oncol Lett; 2021 Dec; 22(6):844. PubMed ID: 34733362
[TBL] [Abstract][Full Text] [Related]
5. MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas.
Mengus C; Schultz-Thater E; Coulot J; Kastelan Z; Goluza E; Coric M; Spagnoli GC; Hudolin T
Int J Cancer; 2013 May; 132(10):2459-63. PubMed ID: 23125074
[TBL] [Abstract][Full Text] [Related]
6. How the Intrinsically Disordered N-Terminus of Cancer/Testis Antigen MAGEA10 Is Responsible for Its Expression, Nuclear Localisation and Aberrant Migration.
Samel A; Väärtnõu F; Verk L; Kurg K; Mutso M; Kurg R
Biomolecules; 2023 Nov; 13(12):. PubMed ID: 38136576
[TBL] [Abstract][Full Text] [Related]
7. Expression of cancer/testis antigens in cutaneous melanoma: a systematic review.
Tio D; Kasiem FR; Willemsen M; van Doorn R; van der Werf N; Hoekzema R; Luiten RM; Bekkenk MW
Melanoma Res; 2019 Aug; 29(4):349-357. PubMed ID: 30615012
[TBL] [Abstract][Full Text] [Related]
8. MAGE-A11 is a potential prognostic biomarker and immunotherapeutic target in gastric cancer.
Wang ZW; Yu QY; Xu MJ; Zhou CY; Li JP; Liao XH
Aging (Albany NY); 2024 Jan; 16(1):285-298. PubMed ID: 38180746
[TBL] [Abstract][Full Text] [Related]
9. Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.
Gunda V; Cogdill AP; Bernasconi MJ; Wargo JA; Parangi S
Surgery; 2013 Dec; 154(6):1456-62; discussion 1462. PubMed ID: 24238058
[TBL] [Abstract][Full Text] [Related]
10. Molecular Characteristics of Bladder Tumor: Increased Gene Expression of MAGE-A6 and MAGE-A11 with Decreased MicroRNA-34a and MicroRNA-125b.
Aghamajidi A; Ousati Ashtiani Z; Mohsenzadegan M; Tajik N; Ghafoori Yazdi M; Sharifi L; Nowroozi MR
Iran J Allergy Asthma Immunol; 2022 Oct; 21(5):561-573. PubMed ID: 36341564
[TBL] [Abstract][Full Text] [Related]
11. MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells.
Yin B; Zeng Y; Liu G; Wang X; Wang P; Song Y
Int J Clin Exp Pathol; 2014; 7(6):2934-41. PubMed ID: 25031712
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic regulation of MAGE family in human cancer progression-DNA methylation, histone modification, and non-coding RNAs.
Lian Y; Meng L; Ding P; Sang M
Clin Epigenetics; 2018 Sep; 10(1):115. PubMed ID: 30185218
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of cancer-testis antigen melanoma-associated antigen A1 in lung cancer: A novel biomarker for prognosis, and a possible target for immunotherapy.
Fanipakdel A; Seilanian Toussi M; Rezazadeh F; Mohamadian Roshan N; Javadinia SA
J Cell Physiol; 2019 Jul; 234(7):12080-12086. PubMed ID: 30569450
[TBL] [Abstract][Full Text] [Related]
14. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer.
Bergeron A; Picard V; LaRue H; Harel F; Hovington H; Lacombe L; Fradet Y
Int J Cancer; 2009 Sep; 125(6):1365-71. PubMed ID: 19533752
[TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases.
Lee AK; Potts PR
J Mol Biol; 2017 Apr; 429(8):1114-1142. PubMed ID: 28300603
[TBL] [Abstract][Full Text] [Related]
16. Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics.
Lerut E; Van Poppel H; Joniau S; Gruselle O; Coche T; Therasse P
Int J Clin Exp Pathol; 2015; 8(8):9522-32. PubMed ID: 26464715
[TBL] [Abstract][Full Text] [Related]
17. [Expression of MAGE genes and MAGE gene products in human renal and urinary bladder tumor].
Ma M; Yu LZ; Na YQ; Geng L; Li HW; Yang XY; Wang Y; Ding Y; Pan BN
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):159-63. PubMed ID: 15100734
[TBL] [Abstract][Full Text] [Related]
18. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis.
Güre AO; Stockert E; Arden KC; Boyer AD; Viars CS; Scanlan MJ; Old LJ; Chen YT
Int J Cancer; 2000 Mar; 85(5):726-32. PubMed ID: 10699956
[TBL] [Abstract][Full Text] [Related]
19. Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis.
Zou C; Shen J; Tang Q; Yang Z; Yin J; Li Z; Xie X; Huang G; Lev D; Wang J
Cancer; 2012 Apr; 118(7):1845-55. PubMed ID: 22009167
[TBL] [Abstract][Full Text] [Related]
20. MAGE-I proteins and cancer-pathways: A bidirectional relationship.
Pascucci FA; Escalada MC; Suberbordes M; Vidal C; Ladelfa MF; Monte M
Biochimie; 2023 May; 208():31-37. PubMed ID: 36403755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
